Express Healthcare

As advanced therapies enter India, can health insurance keep up?

Trupti Balasubramaniam, CEO & Principal Officer, Probus, highlights the gaps in health insurance coverage for advanced therapies and the need for policy innovation to address the costs of emerging treatments.

0 10

Not long ago, an oncologist telling an Indian family that the patient’s own immune cells could be extracted, re-engineered in a laboratory, and then put back into the body to hunt down cancer would have been describing a treatment available only abroad—at a cost most households could not even imagine. Today, that conversation is taking place in Indian hospitals, with a therapy developed and manufactured in India.

That is real progress. But it has also created a problem that nobody particularly likes discussing. The family’s next question is no longer a medical one. It is: Will our health insurance policy pay for this treatment?

Too often, the honest answer is “It depends on the fine print.” Indian health insurance has largely evolved around a simple understanding of illness: you are admitted, you receive treatment, and a bill is generated. CAR-T cell therapy, gene therapy, and newer immunotherapies do not fit neatly into that traditional framework—and the gap is beginning to show.

A policy built for hospital beds

To be fair, insurers have not stood still. Since 2019, the regulator has required health insurance policies to cover a range of modern treatments, including robotic surgery, oral chemotherapy, and immunotherapy. To manage the high and unpredictable costs associated with these new technologies, policies often use structured sub-limits. However, as medical costs continue to evolve, a standard sub-limit can unintentionally leave a significant portion of advanced therapy costs uncovered for the patient.

Cell and gene therapies stretch the old model even further. A conventional claim is relatively straightforward to understand room rent, surgeon’s fees, medicines, and consumables. CAR-T therapy does not come with such a tidy bill. The patient’s cells are collected, sent to a manufacturing facility, engineered over a few weeks, and then infused back into the patient. Around this process are genetic tests, conditioning chemotherapy, a closely monitored hospital stay, and, in some cases, days in the ICU if the immune system overreacts.

This raises a fascinating question for the entire ecosystem: How do we classify a treatment that is part drug, part procedure, and part hospital stay?

It is an entirely new frontier. For now, dedicated claims teams are doing the heavy lifting of mapping these modern medical milestones within traditional policy frameworks, paving the way for clearer and updated guidelines that will ultimately benefit everyone.

Cheaper is not the same as affordable

India’s homegrown CAR-T therapies are reported to cost approximately ₹30 lakh to ₹50 lakh, while comparable treatment in the US can cost several crores. That is a remarkable achievement and one that deserves to be acknowledged.

But ask a salaried family in urban India what ₹40 lakh means. It could represent the down payment on a home, a child’s education fund, and a significant portion of their retirement corpus—all at once. And the cost of the therapy itself is not the final bill. Diagnostic tests, hospitalisation, management of side effects, and months of follow-up care can add substantially to the overall cost.

The usual advice—buy a higher sum insured—misses the point. A ₹1 crore sum insured offers little comfort if the policy’s advanced-therapy clause caps the payout at a fraction of that amount, or excludes the treatment altogether.

What needs to change

None of this is an argument for insurers to pay for every treatment simply because it comes with a new name. These therapies are still relatively young. Long-term data remains limited, outcomes can vary from patient to patient, and a single claim can potentially equal the cost of hundreds of conventional claims. An insurer that carefully manages these risks is doing exactly what it should—protecting the financial stability of the entire pool of policyholders.

What the ecosystem can collectively strive for is greater clarity. When a policy covers advanced therapies, clearly outlining how it supports each stage—from initial diagnostics and cell collection to treatment and recovery—can provide families with much-needed peace of mind. They can then focus entirely on recovery, with a clear understanding of how their insurance coverage supports them.

There is also a significant opportunity for product innovation. Introducing dedicated cell and gene therapy benefits, or modular riders specifically designed for advanced care, would allow the industry to provide clear and robust protection alongside traditional health insurance covers. Looking abroad, some markets are even piloting outcome-based models, where risks are shared between insurers and drugmakers. India’s dynamic healthcare and insurance market is well positioned to explore similar collaborative approaches.

The only question that counts

A family facing a medical crisis does not need to understand the complex mechanisms working behind the scenes. They simply want the reassurance that when a doctor recommends a cutting-edge treatment, their health insurance will stand alongside them as an active partner in their recovery.

For decades, health insurance in India has essentially meant protection against an unexpected hospital bill. Today, the nature of healthcare is changing. Medical science has evolved, and regulations are evolving alongside it. Insurers that proactively develop clear, forward-looking frameworks today will be better placed to build deep, generational trust with Indian families—and help secure a healthier future for everyone.

 

- Advertisement -

Leave A Reply

Your email address will not be published.